|
|
Time |
Source |
|
Announcement
|
|
| 09 Apr 2021 |
9:30 pm |
GNW
|
|
|
Biogen Inc. |
Biogen Announces Two New Nominees for Election to Board of Directors |
| 08 Apr 2021 |
12:00 pm |
GNW
|
|
|
Biogen Inc. |
Biogen and Bio-Thera Solutions Announce Commercialization and License Agreement for Proposed Biosimilar Currently in Phase 3 With the Potential to Treat Moderate to Severe Rheumatoid Arthritis |
| 07 Apr 2021 |
12:30 pm |
GNW
|
|
|
Biogen Inc. |
The European Commission Grants Marketing Authorization for New Subcutaneous Administration of TYSABRI® (natalizumab) to Treat Relapsing-Remitting Multiple Sclerosis |
| 04 Mar 2021 |
12:47 pm |
GNW
|
|
|
Biogen Inc. (0R1B) |
Biogen Announces Plans to Build a New, State-of-the-Art Gene Therapy Manufacturing Facility in Research Triangle Park, North Carolina |
| 24 Feb 2021 |
12:30 pm |
GNW
|
|
|
Biogen Inc. (0R1B) |
Life Science Cares and Biogen Foundation Help Launch Food For Free’s Just Eats Program |
| 11 Feb 2021 |
1:03 pm |
GNW
|
|
|
Biogen Inc. (0R1B) |
Biogen Announces the Expiration Date Results of Its Cash Tender Offer |
| |
1:00 pm |
GNW
|
|
|
Biogen Inc. (0R1B) |
Biogen Announces the Expiration Date Results of Its Private Exchange Offer |
| 10 Feb 2021 |
6:02 pm |
GNW
|
|
|
Biogen Inc. (0R1B) |
Biogen Announces the Pricing Terms of its Cash Tender Offer |
| |
6:00 pm |
GNW
|
|
|
Biogen Inc. (0R1B) |
Biogen Announces the Pricing Terms of Its Private Exchange Offer |
| 04 Feb 2021 |
2:02 pm |
GNW
|
|
|
Biogen Inc. (0R1B) |
Biogen Announces Cash Tender Offer for 5.200% Senior Notes Due 2045 Open to Certain Holders Only |
| |
2:00 pm |
GNW
|
|
|
Biogen Inc. (0R1B) |
Biogen Announces Private Exchange Offer for 5.200% Senior Notes Due 2045 Open to Certain Investors |
| 01 Feb 2021 |
12:30 pm |
GNW
|
|
|
Biogen Inc. (0R1B) |
Biogen Announces FDA Approval of PLEGRIDY® (peginterferon beta-1a) Intramuscular Administration for Multiple Sclerosis |
| 29 Jan 2021 |
12:30 pm |
GNW
|
|
|
Biogen Inc. (0R1B) |
Biogen and Eisai Announce FDA’s 3-Month Extension of Review Period for the Biologics License Application for Aducanumab |
| 11 Jan 2021 |
12:30 pm |
GNW
|
|
|
Biogen Inc. (0R1B) |
Biogen to Launch Pioneering Study to Develop Digital Biomarkers of Cognitive Health Using Apple Watch and iPhone |
| 08 Jan 2021 |
12:30 pm |
GNW
|
|
|
Biogen Inc. (0R1B) |
Biogen Announces First Patient Treated in RESPOND Study Evaluating Benefit of SPINRAZA® (nusinersen) in Patients Treated With Zolgensma® (onasemnogene abeparvovec) |
| 21 Dec 2020 |
12:30 pm |
GNW
|
|
|
Biogen Inc. (0R1B) |
The European Commission Grants Marketing Authorization for PLEGRIDY® (peginterferon beta-1a) Intramuscular Administration for Relapsing-Remitting Multiple Sclerosis |
| 10 Dec 2020 |
3:30 am |
GNW
|
|
|
Biogen Inc. (0R1B) |
Biogen Files New Drug Application for Aducanumab in Japan |
| 27 Nov 2020 |
12:30 pm |
GNW
|
|
|
Biogen Inc.; Sage Therapeutics (0R1B) |
Biogen and Sage Therapeutics Announce Global Collaboration to Develop and Commercialize Potential Breakthrough Therapies in Depression and Movement Disorders |
| 18 Nov 2020 |
12:00 pm |
GNW
|
|
|
Biogen Inc. (0R1B) |
Samsung Bioepis and Biogen Announce FDA Filing Acceptance of SB11, A Proposed Biosimilar Referencing Lucentis® (ranibizumab) |
| 16 Nov 2020 |
12:30 pm |
GNW
|
|
|
Biogen Inc. (0R1B) |
Biogen Ranked #1 Biotechnology Company by Dow Jones Sustainability World Index for an Industry Record 5th Time; Recognition Reflects Longstanding ESG Leadership |
| 07 Nov 2020 |
1:15 am |
GNW
|
|
|
Biogen Inc. (0R1B) |
Update on FDA Advisory Committee’s Meeting on Aducanumab in Alzheimer’s Disease |
| 03 Nov 2020 |
12:30 pm |
GNW
|
|
|
Biogen Inc. (0R1B) |
Biogen to Present Positive Phase 2 Systemic Lupus Erythematosus Data at American College of Rheumatology 2020 Meeting |
| 30 Oct 2020 |
11:00 am |
GNW
|
|
|
Biogen Inc. (0R1B) |
European Medicines Agency Accepts Biogen’s Aducanumab Marketing Authorization Application for Alzheimer's Disease |
| 06 Oct 2020 |
12:00 pm |
GNW
|
|
|
Biogen Inc.; Samsung Bioepis (0R1B) |
Samsung Bioepis and Biogen Announce EMA Filing Acceptance of SB11, a Proposed Biosimilar Referencing Lucentis® (ranibizumab) |
| 14 Sep 2020 |
12:30 pm |
GNW
|
|
|
Biogen Inc. (0R1B) |
Biogen to Invest $250 Million in a 20-year Initiative to Eliminate its Use of Fossil Fuels and Improve Public Health |
| 11 Sep 2020 |
1:01 pm |
GNW
|
|
|
Biogen Inc. (0R1B) |
New Data at ACTRIMS-ECTRIMS Meeting Showcase Safety and Efficacy of Biogen’s Industry-Leading MS Portfolio |
| 08 Sep 2020 |
12:30 pm |
GNW
|
|
|
Biogen Inc. (0R1B) |
New Biogen Data Presented at ACTRIMS-ECTRIMS Advance Understanding of Clinical and Health Disparities in MS |
| 07 Aug 2020 |
12:30 pm |
GNW
|
|
|
Biogen Inc. (0R1B) |
FDA Accepts Biogen’s Aducanumab Biologics License Application for Alzheimer's Disease with Priority Review |
| 06 Aug 2020 |
1:02 pm |
GNW
|
|
|
Biogen Inc.; Denali Therapeuti (0R1B) |
Biogen and Denali to Collaborate on LRRK2 Program for Parkinson’s Disease and Certain TV Platform-Enabled Programs for Neurodegenerative Diseases |
| 24 Jul 2020 |
9:06 pm |
GNW
|
|
|
Biogen Inc. (0R1B) |
Biogen to Present Data at Virtual 2020 Alzheimer’s Association International Conference Highlighting Comprehensive Approach to Alzheimer’s Disease |
| 21 Jul 2020 |
11:00 pm |
GNW
|
|
|
Biogen Inc. (0R1B) |
Biogen Names Michael McDonnell as Executive Vice President and Chief Financial Officer |
| |
12:30 pm |
GNW
|
|
|
Biogen Inc. (0R1B) |
Biogen Plans to Initiate Phase 4 Study Evaluating Benefit of SPINRAZA® (nusinersen) in Patients Treated with Zolgensma® (onasemnogene abeparvovec) |
| 08 Jul 2020 |
10:01 pm |
GNW
|
|
|
Biogen Inc. (0R1B) |
The New England Journal of Medicine Publishes Final Results from Phase 1/2 Study of Tofersen for a Genetic Form of ALS |
| |
12:30 pm |
GNW
|
|
|
Biogen Inc. (0R1B) |
Biogen Completes Submission of Biologics License Application to FDA for Aducanumab as a Treatment for Alzheimer’s Disease |
| 10 Jun 2020 |
12:30 pm |
GNW
|
|
|
Biogen Inc. (0R1B) |
New Results From Landmark NURTURE Study Show That Pre-Symptomatic SMA Patients Treated With SPINRAZA® (nusinersen) Continue to Demonstrate Sustained Benefit From Treatment |
| 04 Jun 2020 |
12:30 pm |
GNW
|
|
|
Biogen Inc. (0R1B) |
Biogen Presents Positive Phase 2 Cutaneous Lupus Erythematosus (CLE) Data at European E-Congress of Rheumatology (EULAR) 2020 |
| 28 May 2020 |
12:30 pm |
GNW
|
|
|
Biogen Inc. (0R1B) |
Biogen and MIT Launch New Virtual Learning Lab for High School Students Historically Underrepresented in Science |
| 19 May 2020 |
12:30 pm |
GNW
|
|
|
Biogen Inc. (0R1B) |
New Data at AAN Showcase Biogen’s Commitment to Advancing Innovation in MS |
| 18 May 2020 |
12:30 pm |
GNW
|
|
|
Biogen Inc. (0R1B) |
New SPINRAZA® (nusinersen) Data Reinforce Sustained Efficacy and Longer-Term Safety Across Broad Range of Spinal Muscular Atrophy (SMA) Patients |
| 27 Apr 2020 |
9:06 pm |
GNW
|
|
|
Biogen Inc. (0R1B) |
Biogen Prices $3.0 Billion of Senior Unsecured Notes |
| 20 Apr 2020 |
10:45 pm |
GNW
|
|
|
Biogen Inc. (0R1B) |
Biogen Releases 2019 Corporate Responsibility Report Demonstrating Continuous Progress Across Environmental, Social and Governance Metrics |
| 16 Apr 2020 |
12:30 pm |
GNW
|
|
|
Biogen Inc. (0R1B) |
Biogen, Broad Institute of MIT and Harvard, Partners HealthCare Launch Consortium to Build and Share a COVID-19 Biobank |
| 02 Apr 2020 |
12:30 pm |
GNW
|
|
|
Biogen Inc. (0R1B) |
Biogen Announces First Patient Treated With Higher Dose of SPINRAZA® (nusinersen) in Phase 2/3 DEVOTE Study |
| 16 Mar 2020 |
8:09 pm |
GNW
|
|
|
Biogen Inc. (0R1B) |
Biogen Foundation Commits $10 Million to Support COVID-19 Relief Efforts in the U.S. and Around the World |
| 27 Feb 2020 |
9:06 pm |
GNW
|
|
|
Biogen Inc.; Sangamo Therapeut (0R1B) |
Biogen and Sangamo Announce Global Collaboration to Develop Gene Regulation Therapies for Alzheimer’s, Parkinson’s, Neuromuscular, and Other Neurological Diseases |
| 13 Jan 2020 |
12:30 pm |
GNW
|
|
|
Biogen Inc. (0R1B) |
Biogen to Acquire Novel Clinical Stage Asset with Application in Alzheimer’s Disease and Parkinson’s Disease from Pfizer Inc. |
| 13 Dec 2019 |
12:30 pm |
GNW
|
|
|
Biogen Inc. (0R1B) |
Biogen Reports Top-Line Results from Phase 2 Study in Progressive Supranuclear Palsy |
| 03 Dec 2019 |
12:30 pm |
GNW
|
|
|
Biogen Inc. (0R1B) |
Biogen Announces Positive Phase 2 Study Results for Cutaneous Lupus Erythematosus (CLE) and Systemic Lupus Erythematosus (SLE) |
| 22 Nov 2019 |
12:30 pm |
GNW
|
|
|
Biogen Inc. (0R1B) |
Biogen Presents Data Demonstrating Improved Gastrointestinal Tolerability With VUMERITY™ (diroximel fumarate) Compared to TECFIDERA® (dimethyl fumarate) |
| 21 Nov 2019 |
12:30 pm |
GNW
|
|
|
Biogen Inc. (0R1B) |
Biogen Announces Enrollment Completion of Global Phase 3 Gene Therapy Study for an Inherited Retinal Disorder |
| 06 Nov 2019 |
12:30 pm |
GNW
|
|
|
Biogen Inc. (0R1B) |
Biogen to Expand Biosimilars Portfolio and Gain Access to Additional Markets Through New Transaction with Samsung Bioepis |
| 04 Nov 2019 |
9:30 pm |
GNW
|
|
|
Biogen Inc. (0R1B) |
Biogen to Host Investor Webcasts from Clinical Trials on Alzheimer’s Disease (CTAD) Congress on December 5, 2019 |
| 30 Oct 2019 |
11:30 am |
GNW
|
|
|
Biogen Inc. (0R1B) |
Biogen and Alkermes Announce FDA Approval of VUMERITY™ (diroximel fumarate) for Multiple Sclerosis |
| 22 Oct 2019 |
11:30 am |
GNW
|
|
|
Biogen Inc. (0R1B) |
Biogen Plans Regulatory Filing for Aducanumab in Alzheimer’s Disease Based on New Analysis of Larger Dataset from Phase 3 Studies |
| 21 Oct 2019 |
12:30 pm |
GNW
|
|
|
Biogen Inc. (0R1B) |
Biogen and Samsung Bioepis to Present Data for Infliximab and Adalimumab Biosimilars at United European Gastroenterology Week |
| 02 Oct 2019 |
12:30 pm |
GNW
|
|
|
Biogen Inc. (0R1B) |
Landmark NURTURE Study of Infants with Spinal Muscular Atrophy (SMA) Treated Pre-Symptomatically with SPINRAZA® (nusinersen) Published in Neuromuscular Disorders |
| 01 Oct 2019 |
1:00 pm |
GNW
|
|
|
Biogen Inc. (0R1B) |
Biogen Announces Leadership Update |
| 23 Sep 2019 |
8:00 am |
GNW
|
|
|
Biogen Inc. (0R1B) |
Interferon Beta Treatments, Including PLEGRIDY® (peginterferon beta-1a) and AVONEX® (interferon beta-1a), Receive Positive CHMP Opinion for Use During Pregnancy and Breastfeeding |
| 18 Sep 2019 |
12:30 pm |
GNW
|
|
|
Biogen Inc. (0R1B) |
Biogen Advances Spinal Muscular Atrophy (SMA) Clinical Research with New Study Evaluating a Higher Dose of SPINRAZA® (nusinersen) and Additional Data in a Broad Range of Patients |
| 17 Sep 2019 |
12:30 pm |
GNW
|
|
|
Biogen Inc. (0R1B) |
Biogen Ranked #1 Biotechnology Company on Dow Jones Sustainability World Index |